Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 5.30%, which has investors questioning if this is right time to buy.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Inhibikase Therapeutics (IKT) announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.Stay Ahead of ...

Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.

Inhibikase Therapeutics BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical ...

BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH), announced today the ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small ...

(MENAFN- GlobeNewsWire - Nasdaq) BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or“Company ...

(RTTNews) - Inhibikase Therapeutics, Inc. (IKT), a pharmaceutical company, on Monday announced that it has appointed David McIntyre as Chief Financial Officer, effective from April 14. Shares of ...